Barbara Castella
YOU?
Author Swipe
View article: Preclinical efficacy of carfilzomib in <i>BRAF</i> ‐mutant colorectal cancer models
Preclinical efficacy of carfilzomib in <i>BRAF</i> ‐mutant colorectal cancer models Open
Serine/threonine‐protein kinase B‐raf ( BRAF ) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF‐ mutant human cell…
View article: Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity Open
View article: Supplementary Figures from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Figures from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Figure S1. ALK Tg mice develop lung multifocal adenocarcinomas similar to human ALK-rearranged NSCLC. Supplementary Figure S2. Therapeutic ALK vaccine impairs tumor growth of ALK-rearranged lung tumors. Supplementary Figure S…
View article: Data from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Data from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors (TKI), but the treatment is successful for only a limited amount of …
View article: Supplementary Figure Legends from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Figure Legends from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Figure Legends
View article: Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Materials and Methods
View article: Data from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Data from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors (TKI), but the treatment is successful for only a limited amount of …
View article: Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Materials and Methods
View article: Supplementary Figure Legends from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Figure Legends from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Figure Legends
View article: Supplementary Figures from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors
Supplementary Figures from Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors Open
Supplementary Figure S1. ALK Tg mice develop lung multifocal adenocarcinomas similar to human ALK-rearranged NSCLC. Supplementary Figure S2. Therapeutic ALK vaccine impairs tumor growth of ALK-rearranged lung tumors. Supplementary Figure S…
View article: Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status Open
Introduction Bone marrow (BM) Vγ9Vδ2 T cells are intrinsically predisposed to sense the immune fitness of the tumor microenvironment (TME) in multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). Methods In t…
View article: Molecular dynamics of targeting CD38 in multiple myeloma
Molecular dynamics of targeting CD38 in multiple myeloma Open
Summary Multiple functions of CD38 need exploring to expand clinical application of anti‐CD38 antibodies in multiple myeloma (MM). We investigated membrane dynamics of MM cells and subsequent events when CD38 is targeted by therapeutic ant…
View article: Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia
Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia Open
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
View article: CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab Open
CD38-targeted therapy is emerging as one of the most effective immunotherapies ever developed for the treatment of multiple myeloma (MM) 1. CD38 is a transmembrane glycoprotein that serves as a receptor with a multifunctional ecto-enzymati…
View article: Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells
Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells Open
Doxorubicin (dox) is one of the first-line drug treatment in osteosarcoma. P-glycoprotein (Pgp) limits dox’s intracellular accumulation and efficacy in osteosarcoma. Part of the cytotoxic effects of dox are mediated by the induction of imm…
View article: Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer Open
View article: Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma Open
The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance t…
View article: Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression Open
Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is o…
View article: ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells Open
Human Vγ9Vδ2 T cells have the capacity to detect supra-physiological concentrations of phosphoantigens (pAgs) generated by the mevalonate (Mev) pathway of mammalian cells under specific circumstances. Isopentenyl pyrophosphate (IPP) is the…
View article: Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD<sup>+</sup>
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD<sup>+</sup> Open
Multiple myeloma (MM) derives from malignant transformation of plasma cells (PC), which accumulate in the bone marrow (BM), where microenvironment supports tumor growth and inhibits anti-tumor immune responses. Adenosine (ADO), an immunosu…
View article: The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells Open
View article: Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia Open
In chronic lymphocytic leukemia (CLL) the occurrence and the impact of antibody responses toward tumor-derived antigens are largely unexplored. Our serological proteomic data show that antibodies toward 47 identified antigens are detectabl…
View article: Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors
Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors Open
Non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors (TKI), but the treatment is successful for only a limited amount of time; m…
View article: Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells Open
The immunoglobulin heavy-chain variable region (IGHV) mutational status is a strong determinant of remission duration in chronic lymphocytic leukemia (CLL). The aim of this work was to compare the multidrug resistance (MDR) signature of IG…
View article: Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma Open
Vγ9Vδ2 T cells have a natural inclination to recognize malignant B cells in vitro via receptors for stress-induced self-ligands and TCR-dependent recognition of phosphoantigens (pAgs) generated in the mevalonate (Mev) pathway. This …
View article: An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells Open
BackgroundMultidrug resistant cancer cells are hard to eradicate for the inefficacy of conventional anticancer drugs. Besides escaping the cytotoxic effects of chemotherapy, they also bypass the pro-immunogenic effects induced by anticance…